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Abstract  28 
Human liver cancer research currently lacks in vitro models that faithfully recapitulate the 29 
pathophysiology of the original tumour. We recently described a novel, near-physiological 30 
organoid culture system, where primary human healthy liver cells form long-term expanding 31 
organoids that retain liver tissue function and genetic stability. Here, we extend this culture 32 
system to the propagation of primary liver cancer (PLC) organoids from three of the most 33 
common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and 34 
combined HCC/CC (CHC) tumours. PLC-derived organoid cultures preserve the histological 35 
architecture, gene expression and genomic landscape of the original tumour, allowing 36 
discrimination between different tumour tissues and subtypes, even after long term expansion 37 
in culture in the same medium conditions. Xenograft studies demonstrate that the 38 
tumourogenic potential, histological features and metastatic properties of PLC-derived 39 
organoids are preserved in vivo. PLC-derived organoids are amenable for biomarker 40 
identification and drug screening testing and lead to the identification of the ERK inhibitor 41 
SCH772984 as a potential therapeutic agent for primary liver cancer. We thus demonstrate 42 
the wide-ranging biomedical utilities of PLC-derived organoid models in furthering the 43 
understanding of liver cancer biology and in developing personalized medicine approaches 44 
for the disease. 45 
  46 
 2
Primary liver cancer (PLC) is the second most lethal malignancy worldwide, with incidence 47 
rates rising, mainly due to an increase in associated risk factors like diabetes or obesity1,2. The 48 
majority of all PLC are classified into either hepatocellular carcinoma (HCC) or 49 
cholangiocarcinoma (CC)3. There is also a combined hepatocellular-cholangiocarcinoma 50 
(CHC) subtype, which accounts for 0.4 to 14.2% of all PLCs4. Albeit HCC and CC are easily 51 
distinguishable by their histological appearance2,5, genetic and transcriptional landscapes6, 52 
with CHC sharing features of both7, PLC is overall a complex entity, which renders each case 53 
of the disease unique and in need of personalized treatment.  54 
 55 
The development of effective treatments for liver cancer has been hindered by the shortage of 56 
reproducible human models to assess the efficacy of candidate therapeutic agents8. 57 
Historically, preclinical models have mainly consisted of genetically engineered mouse 58 
models or human tumour-derived cell lines propagated in either 2D-culture or as xenografts 59 
in mice8-10. While 2D-culture has allowed pioneering advances in cancer biology, it fails to 60 
recapitulate critical features of a growing tumour in vivo11, specially the 3D organization. In 61 
addition, CCs have proven difficult to propagate in vitro12,13.  62 
 63 
Recent reports of culture systems of primary, non-transformed tissues growing as 3D 64 
structures, termed organoids, accurately recapitulate tissue architecture and function. Thus 65 
retinal, cerebral, kidney, intestinal and stomach organoids (among others)14 have already been 66 
generated from pluripotent stem cells for the study of human development and disease. In 67 
addition, organoids are promising disease models not only for understanding the biology but 68 
also for testing drug efficacy in vitro, before moving to animal models15. Accordingly, mouse 69 
and human cancer organoids have recently been established for colon16-19, pancreas17,20 and 70 
prostate21 tumours, but not, thus far, from liver tumours. 71 
 72 
Based on our previous work in mouse liver and pancreas organoid cultures22-23, we recently 73 
showed that organoid cultures derived from human liver donor/healthy tissues could be 74 
expanded long-term in vitro while preserving most of their liver functionality and genetic 75 
stability over time24. Here, we demonstrate the proof-of-concept that liver organoid cultures 76 
also recapitulate human primary liver cancer in vitro. Hence, we have successfully established 77 
organoid cultures from 8 PLC patients, encompassing three of the most common subtypes of 78 
PLC3: HCC, CC and CHC. PLC-derived organoids recapitulate the histological architecture, 79 
expression profile, genomic landscape and in vivo tumourigenesis of the parental tumour, 80 
even after long-term expansion in culture. In addition, we demonstrate the utility of PLC-81 
derived organoids for identifying genes with prognostic value for PLC and potential novel 82 
therapeutic targets, thus opening up opportunities for drug testing and advances in 83 
personalized medicine approaches. 84 
  85 
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RESULTS 86 
 87 
Liver cancer organoids maintain the features of the parental tumour after long-term in 88 
vitro expansion. 89 
We have recently established culture conditions for the long-term expansion of human cells 90 
derived from liver donor/healthy tissues24,25. Here, we sought to selectively expand tumour 91 
cells from human PLC tissue by optimizing our established human liver expansion protocol. 92 
Surgically resected liver tumour tissue was obtained from untreated PLC patients who had no 93 
history of viral-meditated hepatitis. Specimens (~1cm3 tissue) from the 3 main PLC subtypes 94 
were obtained and each individual sample was split into 4 parts that were either processed for 95 
organoid derivation, histological diagnostic, genomic or transcriptomic analyses (Fig. 1a-b). 96 
We observed that normal/healthy contaminating tissue within the samples gave rise to 97 
organoids that would quickly outcompete the tumour-derived organoids, presumably due to 98 
differences in genetic stability, as previously suggested19. Therefore, to avoid the growth of 99 
healthy contaminating organoids, we modified our derivation protocol by (i) increasing the 100 
timing of tissue digestion, which reduced the yield of healthy contaminants; (ii) changing the 101 
starting culture conditions using, in addition of the classical isolation medium24,25, a newly 102 
defined PLC-derived organoids isolation medium consisting in the classical isolation 103 
medium24,25 without R-spondin-1, Noggin and Wnt3a but supplemented with Dexamethasone 104 
and Rho-kinase inhibitor for at least 2 weeks (Fig. 1c) and (iii) closely monitoring the 105 
developing organoid structures. Particularly, for all the samples in the manuscript we cultured 106 
half of the cell suspension in classical isolation medium and the other half in our tumouroid 107 
specific isolation medium, to ensure growth of the cultures (Supplementary Fig. 1 & 108 
methods). At the first passage all cultures (healthy and tumour, irrespective of their subtype-109 
of-origin) were transferred to our previously defined “human healthy liver-derived organoids 110 
expansion medium”24,25 and expanded and maintained in this medium. 111 
 112 
Using this novel protocol, we successfully established human PLC-derived organoids from 8 113 
different PLC patients, including poorly differentiated to moderate/well differentiated HCC 114 
(n=3) and CC (n=3), and combined HCC/CC (CHC; n=2) (Fig. 1, Supplementary Fig. 2a and 115 
Supplementary Table 1). We found a strong correlation between the derivation success rate 116 
(establishment) and the proliferation index of the original tumour. Thus, the efficiency of 117 
establishment of organoid cultures was 100% for those samples derived from tumours that 118 
contained > 5% proliferating cells (n=3 for HCC; n=2 for CHC and n=3 for CC), while we 119 
did not succeed in deriving organoids from very well differentiated lesions, with <5% 120 
proliferative cells in the original samples (n=8 for HCC and n=1 for CC), in agreement with 121 
the histological grading of early HCCs5 (Supplementary Fig. 2b-g and Supplementary Table 122 
1).  123 
PLC-derived organoids (termed “tumouroids” henceforth) from all 3 different subtypes 124 
expanded long-term (~1year) in culture, with a consistent passaging ratio of 1:3-1:4 every 7-125 
10 days. HCC-2, though, stopped growing after ~1 month, due to fibroblasts outcompeting 126 
the tumouroids growth, which precluded any downstream analysis. Therefore, we have 127 
performed all the downstream analysis on the remaining 7 lines and corresponding patient’s 128 
tissues (HCC-1 and -3; CHC-1-2 and CC-1-3) (Fig. 1d and Supplementary Fig. 2h).  129 
At the histological level, tumouroids presented patient-specific heterogeneous morphologies 130 
ranging from solid/compact structures (HCC and CHC) to more irregularly-shaped cyst-like 131 
structures (CC) in contrast to the ordered, homogeneous, cyst-like hollow structure of healthy 132 
liver-derived organoids (Fig. 1b and SupplementaryFig. 2a). These morphological features 133 
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allowed individual samples to be distinguished from each other, both within and between 134 
subtypes, even at late passage and after having been cultured for months in the same 135 
conditions. 136 
We then sought to determine whether the 3D-tumouroids would retain the histological 137 
features of the patient tumour tissue. Healthy liver-derived organoids form single-layered 138 
epithelial structures that transition into a pseudo-stratified epithelium upon differentiation (see 139 
ref 24 for details). In contrast, the tumouroids exhibited a very different histological and 140 
cellular architecture, which recapitulated the histological features of the patient’s tissue and 141 
tumour subtype. Thus, HCC and CHC tumouroids exhibited a solid, filled 3D structure with 142 
HCCs, but not CHCs, also forming pseudoglandular rosettes, typical of HCC3,7. Similarly, CC 143 
tumouroids exhibited extensive glandular domains with carcinoma cells invading the lumen 144 
and growing in cribriform structures, as observed in the patient’s tissue (Fig. 1b and 145 
Supplementary Fig. 2a).  146 
Detailed histological and marker analysis of all the patient’s tumour tissues revealed that our 147 
cultures derived from a moderate/well differentiated HCC (HCC-1; AFP+/HepPar1+), a 148 
poorly differentiated HCC (HCC-3; AFP+/HepPar1-), a classical combined (CHC-1; 149 
AFP±/HepPar1+/EpCAM+/mucin+), a combined with stem cell features (CHC-2; 150 
AFP+/HepPar1+/EpCAM+/mucin-) and poorly to moderate/well differentiated CCs (CC-1-3; 151 
HepPar1-/EpCAM+) (Fig. 2a-b, Supplementary Fig. 3a-c and Supplementary Table 1)26. 152 
Subsequent analysis of these subtype-specific markers in the tumouroids revealed that these 153 
express the diagnostic markers of their parental tissues, even after long-term expansion in 154 
culture in the same culture conditions. Thus, EpCAM, was highly expressed in all CCs (CC-155 
1-3) and CHCs (CHC-1-2) tumouroids and corresponding patients’ tissues, but absent on 156 
HCCs tumouroids and tissues (Fig. 2c and Supplementary Fig.3b). Likewise, AFP a well-157 
established marker for HCCs and a subset of CHCs27, but not expressed in CCs3,5,28-29, was 158 
highly expressed in both HCCs and CHC-2 tumouroids, in agreement with the expression 159 
pattern of the original patient’s tissue (Fig. 2c and Supplementary Table 1). Remarkably, 160 
SALL4 described for a subset of poorly differentiated HCCs30-31 and CHCs32 was only present 161 
in HCC-3 and CHC-2, both in tumouroids and matching tissues (Supplementary Fig. 3d). 162 
 163 
Overall, these results demonstrate that liver tumouroids both recapitulated and retained the 164 
histological characteristics and marker expression of the original tumour tissue and subtype, 165 
even after long-term expansion in culture, in the same culture conditions. 166 
 167 
Primary Liver Cancer-derived organoid cultures recapitulate the expression profile of 168 
the corresponding tissue-of-origin and tumour subtype.  169 
The gene expression patterns of PLC subtypes (HCC, CC and CHC) have been extensively 170 
studied33-34. Therefore, to further characterize our tumouroid cultures we compared their 171 
expression profiles to the corresponding parental tissues using genome-wide transcriptomic 172 
(RNAseq) analysis. Healthy liver-derived organoid lines and corresponding tissues were used 173 
as additional controls.  174 
 175 
Relative transcript abundance (transcripts per million, RPKM) of 15,648 gene transcripts was 176 
determined. Principal component analysis (PCA) analysis indicated that both technical and 177 
biological replicates per patient were almost identical (Supplementary Fig. 4a-b and 178 
Supplementary Dataset 1). Therefore, we present the data per patient as average of all these 179 
replicates. A first hierarchical clustering analysis comparing the gene expression profiles of 180 
our tissue samples with publically available TCGA PLC cohorts (344 HCC and 31 CC 181 
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samples) confirmed that the samples used in this study are representative of the overall 182 
population of primary liver cancer (Supplementary Fig. 4c and Supplementary Dataset 1). 183 
Then, we compared the expression profiles of these parental tissues to the corresponding 184 
tumouroid lines. Gene expression correlation analysis indicated that each tumouroid line 185 
correlated to its corresponding tissue-of-origin but not with the other subtypes (Fig. 3a). 186 
Along the same line, organoids and tissue samples grouped by subtype on the PC2 187 
component, while the PC1 component accounted for the variance between tissues and 188 
tumour-derived organoids. Classical HCC/hepatocyte markers35 such as AFP or APOH and 189 
CC/ductal markers36 such as KRT7, were amongst the genes that contributed the most to the 190 
variance in the PC2 component (Fig. 3b and Supplementary Dataset 1).  191 
When evaluating specific tumoural/differentiation markers, we found that the tumouroids’ 192 
expression profiles resembled the corresponding matching tissues and subtype 193 
(Supplementary Fig 4d). Notably, we found the HCC markers (AFP and GPC3) and 194 
hepatocyte markers (ALB, TTR, APOA1, APOE) to be highly expressed in our HCC 195 
tumouroids and matching tissue while CC/ductal markers were amongst the most 196 
downregulated. Reciprocally, CC markers such as EPCAM, KRT19 or S100A112,37,38-39 were 197 
highly expressed in our CC lines and tissues, while HCC markers were not expressed or 198 
strongly downregulated. The CHC lines shared the expression pattern of both, as expected 199 
(Fig. 2b-c, Fig. 3b-c, Supplementary Fig. 3b, Supplementary Fig. 4d and Supplementary Fig. 200 
5a-b), and Supplementary Dataset 1). Remarkably, the expression pattern was also retained in 201 
a patient-specific manner even within each subtype. For instance, MUC5B was expressed 202 
only in CHC-1 but not in CHC-2 organoids, in agreement with the corresponding patient’s 203 
tissue (Supplementary Dataset 1 and Supplementary Fig. 3c), whereas AFP was expressed in 204 
CHC-2 but not CHC-1 in concordance with the AFP values in serum of these patients at the 205 
moment of resection (compare Fig. 2c and Supplementary Table 1).  206 
 207 
These results were confirmed by global analysis using Gene-Set-Enrichment-Analysis 208 
(GSEA) of the tumouroid lines and their corresponding parental tissues against 159 published 209 
cancer gene-sets (Fig. 3d and Supplementary Datasets 2 and 3). Thus, for both HCC lines and 210 
corresponding tissues, HCC gene-sets were the most significantly positively enriched, with 211 
HCC-1 associated to gene-sets describing HCC with hepatocyte differentiation features while 212 
HCC-3 significantly associated with a proliferative HCC subclass and a KRT19 positive 213 
subclass gene-sets in agreement with the differentiation status of the patient’s original tissue. 214 
Conversely, for all CC tumouroids and matching tissues, CC gene-sets were the most 215 
significantly positively enriched whereas HCC specific gene-sets were significantly down-216 
regulated, as expected. Similarly, the CHC expression profiles were negatively correlated 217 
with HCC-differentiation gene-sets but positively correlated with progenitor/stem cell, 218 
proliferation and/or poor prognosis gene-sets (Fig. 3d, Supplementary Fig. 5c-d and 219 
Supplementary Dataset 2 and 3).  220 
 221 
Subsequent analyses confirmed the RNAseq results, with HCC but not CC tumouroids 222 
exhibiting hepatocyte differentiation features (ALB and HNF4a expression, Albumin 223 
secretion, and production of bile acid in the medium (the later for HCC-1)) (Supplementary 224 
Fig. 5b, e-f). In contrast, KRT19, marker for CC, CHC tumours2,27 and a subset of HCCs26, 225 
was highly expressed in all CC (CC-1-3), in both CHC (CHC-1-2) and in HCC-3 derived 226 
tumouroids, but undetectable in HCC-1, in agreement with the histological subtype, 227 
expression pattern and gene signature of the patient’s tumour tissue (Supplementary Fig. 5a-b 228 
and d). Moreover, KRT7, a well-established marker for CCs37, was only expressed in the CC-229 
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derived organoids and corresponding tissues (Supplementary Fig. 5f). 230 
 231 
These results demonstrate that the PLC-derived organoid culture system faithfully 232 
recapitulates and maintains the transcriptomic alterations present in the individual patient’s 233 
tumour subtype. Since the different tumour subtypes were all maintained in the same culture 234 
conditions these results suggest that their tumour signature is intrinsic to the cancer 235 
population, and is not significantly modified by the culture conditions. 236 
 237 
Tumouroid/Organoid cultures enable the identification of potential prognostic 238 
biomarkers for primary liver cancer  239 
We next sought to investigate if the tumouroid culture system could represent a valuable 240 
resource to identify novel genes involved in PLC and/or novel potential PLC biomarkers, a 241 
use not previously described for any patient-derived organoid system. For that, we defined a 242 
“tumouroid signature” list by comparing the similarities between the transcriptomes of all 243 
tumouroid lines to healthy liver-derived organoid lines. Notably, within the top 30 most 244 
upregulated genes we found 19 genes already reported to be markers/overexpressed in PLC, 245 
13 of which were already associated to poor-prognosis, while the remaining 11 genes had 246 
never been associated to PLC (Fig. 3e and Supplementary Dataset 1). 247 
 248 
We then performed an in-depth analysis of these top 30 genes by determining their expression 249 
pattern and prognostic value in cohorts of primary liver cancer patients and healthy 250 
individuals from publically available TCGA databases (for HCC: 374 HCC patients and 50 251 
healthy individuals; for CC: 31 CC patients and 8 healthy individuals). Notably, 29 of the top 252 
30 genes were significantly (p≤0.01) overexpressed in cancer patients vs healthy individuals 253 
for both cohorts. Importantly, from the 11 novel genes never associated before to liver cancer, 254 
4 exhibited poor survival prognosis when overexpressed: C19ORF48, UBE2S and DTYMK 255 
(for HCC) and C1QBP (for CC). Of note, STMN1, previously associated to HCC but not 256 
CC40, also predicted poor survival in the CC-cohort (Fig. 3f-h and Supplementary Dataset 1). 257 
Therefore, these results demonstrate that growing primary liver cancer as tumouroids 258 
preserves the tumour-cell features at a level that allows identifying new genes with a 259 
prognostic value and that could potentially be used as prognostic biomarkers for primary liver 260 
cancer. 261 
 262 
Liver tumouroids retain the genetic alterations present in the original tumour tissue. 263 
PLCs typically present with a high degree of aneuploidy, several copy number changes, 264 
somatic mutations and epigenetic alterations6. All the lines that we expanded in culture (HCC, 265 
n=2; CHC, n=2; CC, n=3) exhibited multiple chromosomal aberrations consisting of both 266 
gains and/or losses of chromosome numbers (Fig. 4a-b). This was in stark contrast to healthy 267 
liver-derived organoids that stably maintained diploid chromosome numbers in culture, in 268 
agreement with our previous observations24,41. To determine whether the different tumouroid 269 
lines retain the parent tumour’s mutational landscape, we performed whole exome sequencing 270 
(WES) analysis of each line expanded for short (<2 months, early passage) or extended (>4 271 
months, late passage) periods in culture and compared the results to the corresponding parent 272 
tumour.  273 
 274 
We generated ~19 Gb exome DNA sequence data from each sample. When comparing the 275 
global variant profile, we observed that, on average, ~92% of the variants in the patient’s 276 
tissue were retained in the corresponding early tumouroid cultures (<2months), and >80% 277 
 7
even after months of expansion (Fig. 4c). Similarly, the analysis of the proportion of exonic 278 
variations for both patient’s tissue and corresponding cultures confirmed that both, single 279 
nucleotide variants (SNVs) and Indels in the original tissue, are well retained in culture. Also, 280 
the distribution of base substitutions for both tissues and tumouroids revealed an over-281 
representation of the T>C/A>G and C>T/G>A transversion, in agreement with the mutational 282 
spectrum described for CCs and HCCs42-43 (Fig. 4d-e). Of note, we did not find significant 283 
bias between transcribed and untranscribed strands (Supplementary Fig. 6a).  284 
Since we lacked matched germline (normal/non-tumour) mutational data, in order to select 285 
for cancer related variants we filtered for variants present in COSMIC and excluded 286 
polymorphisms by using publically available databases following the guidelines described in 287 
ref 44 (see methods). The majority of all the cancer-related somatic variants present in the 288 
patient’s original tissue were retained in the corresponding tumouroid cultures (~84%). In 289 
fact, <16% (in average) were lost between tissue and early tumouroids, thus suggesting that 290 
the cultures represent the tumour genetic landscape of the original patient, with little bias of 291 
tumouroids cells harbouring specific mutations (~0.5 % in average) (Fig. 4f). The total 292 
number of deleterious mutations that could impact protein function ranges from 70 to 294, in 293 
agreement with published mutational burdens for HCC and CC tumours42,45 (Supplementary 294 
Fig. 6b, Supplementary Dataset 4).  295 
 296 
Next-generation sequencing studies have created a detailed map of the genetic alterations 297 
present in liver cancer and its subtypes6. In agreement with this mutational spectrum, HCC-1 298 
line and corresponding patient tissue exhibited missense mutations in CTNNB1 (Fig. 4g and 299 
Supplementary Dataset 4), consistently with their significant enrichment in CTNNB1 mutated 300 
liver cancer gene-set found in the gene GSEA (Fig. 3d) and their elevated levels of Wnt target 301 
genes (Supplementary Dataset 1). CHC-2 line harboured a TP53 frameshift variant (L206fs). 302 
Also, we identified an activating mutation in KRAS (KRASG12D) in CC-1 and CHC-1 303 
tumouroid lines and matching tissues, but not in the HCC lines, in agreement with the 304 
significant enrichment in EGF activated gene-set for those lines (Supplementary Fig. 6c)46. 305 
We also found nonsense mutations and a disruptive deletion in the chromatin remodelling 306 
genes ARID1A (HCC-3 and CC-1) and ARID2 (HCC-3), in agreement with previous reports 307 
where both genes are altered in all subtypes of PLC47-48 (Fig. 4g, and Supplementary Dataset 308 
4). As expected, all lines were devoid of mutations in MAPK1 and MAPK3 (ERK1 and ERK2 309 
respectively), as described for PLC45. 310 
 311 
Therefore, these results indicate that the PLC tumouroid culture system retained the 312 
mutational landscape of the original tumour tissue and faithfully retained the tumour subtype 313 
specific mutations present in the original sample from which where derived. 314 
 315 
Tumouroids recapitulate the histology of the parental tumour and show metastatic 316 
potential in vivo 317 
To determine whether tumouroids also recapitulate the features of a human primary liver 318 
tumour in vivo, we transplanted CC (CC-1-3 lines) and HCC-1 long-term expanded 319 
tumouroids under the skin of immunocompromised mice. Healthy liver-derived organoids 320 
were used as controls (Fig. 5a). We found tumour outgrowths in the animals engrafted with 321 
CC-1_O (29/29), CC-2_O (8/8) and HCC-1_O (24/34), but not when injected with healthy 322 
liver-derived organoids (Healthy-1_O) (Fig. 5b and Supplementary Fig. 7a-b). The CC- 323 
derived tumours exhibited a strong stromal reaction with CC-1_O tumours forming glands 324 
with proliferative cells growing in cribriform structures (Fig. 5c Supplementary Fig. 7c, and 325 
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CC-2_O exhibiting a more differentiated phenotype (Supplementary Fig. 7 d), reminiscent of 326 
the corresponding patient’s tumour tissue. Similarly, HCC-1_O derived tumours grew as a 327 
solid mass with proliferative cells (Supplementary Fig. 7c) and exhibited pseudoglandular 328 
rosettes, as in the patient’s tissue (Fig. 5d). Secondary tumouroids derived from these 329 
xenografted tumours exhibited similar chromosome counts and were morphologically and 330 
histologically indistinguishable from their parental line (Supplementary Fig. 7e-f). Hence, this 331 
indicated that even after long-term expansion in vitro and transplantation in vivo, expanding 332 
primary liver tumours in organoid culture, stably preserves the histological architecture of the 333 
parent tumour.  334 
Primary liver cancer has been reported to metastasize primarily to the lung and portal lymph 335 
nodes49. To determine whether our tumouroid models would faithfully recapitulate liver 336 
cancer metastatic phenotype, we injected CC-1_O, derived from a patient with history of 337 
metastasis, into the kidney capsule of NSG mice. As expected, 100% of the injected mice 338 
developed tumours that resembled the original patient tissue (Fig. 5b and e). More 339 
importantly, in 7 out of 9 injected mice we found lung metastases, in agreement with the 340 
patient’s diagnostic at the moment of resection (Supplementary Table 1), while, as expected, 341 
healthy liver-derived organoids (Healthy-1_O) did not generate any metastases (Fig. 5b and f, 342 
Supplementary Fig. 7 g-h) 343 
 344 
Overall, these results establish that primary liver cancer-derived organoids accurately model 345 
the histological and metastatic features of their parent tumours in vivo, even after long-term 346 
expansion in culture.  347 
 348 
Liver tumouroids allow the identification of patient-specific drug sensitivities and 349 
uncover ERK as a potential target for primary liver cancer  350 
We performed proof-of-concept drug sensitivity testing in 6 of the PLC tumouroids lines 351 
(HCC-1; HCC-3; CHC-1,-2; CC-1,-2) to evaluate their use to identify patient-specific 352 
sensitivities and as a platform to inform drug development. As an initial prioritization step, 353 
for each tumouroid line we tested their sensitivity to 29 anti-cancer compounds, including 354 
drugs in clinical use or development. Tumouroids were treated with a dilution series of each 355 
compound for 6 days, before measuring cell viability50. Drug sensitivity was represented by 356 
the area under the dose response curve (AUC) and by the half-maximal inhibitory 357 
concentration (IC50) (Fig. 6a-c and Supplementary Dataset 5). The assay was conducted with 358 
technical replicates and two biological replicates per tumouroid were independently screened. 359 
There was a positive correlation of biological AUC replicates (Rp = 0.79) and IC50 replicates 360 
(Rp = 0.73) across the dataset. CC-2 was insensitive to all compounds and so was excluded 361 
from further analyses.  362 
 363 
From our initial prioritization screen, we confirmed drug sensitivity for a subset of 364 
compounds using a tumouroid formation assay, thus validating our screening method. We 365 
selected clinically relevant compounds where differential sensitivity was observed across the 366 
tumouroid panel; namely Taselisib, Gemcitabine, AZD8931, SCH772984 and Dasatanib (Fig. 367 
6c-d). Overall, a good agreement between the screening and validation results was observed 368 
(Supplementary Fig. 8a). For instance, Taselisib resulted in a growth inhibitory effect in 5 of 369 
6 tumouroids while Dasatinib suppressed tumouroid formation only in CC-1 cells, both 370 
results in agreement with our screening results. An exception was for CC-1 line with 371 
AZD8931, where we observed a variable sensitivity between biological replicates in the 372 
prioritization screen (Fig. 6 c-d, Supplementary Fig. 8a). 373 
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Overall, tumouroids were resistant to the majority of the compounds, with an IC50 greater 374 
than the maximum screening concentration, although we detected interesting sensitivity to 375 
several compounds demonstrating a correlation between some drug sensitivities and 376 
mutational profiles in the tumouroid lines. For instance, HCC-1 harbouring mutations in 377 
CTNNB1 gene, was resistant to the porcupine inhibitor LGK974, whereas CC-1, Wnt-378 
dependant tumour (Fig.1c), was sensitive (Fig. 6a-c). Moreover, EGFR-family inhibition with 379 
AZD8931 restricted tumouroid formation in HCC-1 cells (wild-type for KRAS), whereas the 380 
other lines, and notably CC-1 and CHC-1 (KRAS mutants) were resistant. Interestingly we 381 
also observed tumouroid sensitivity to Gemcitabine, which is used clinically for the treatment 382 
of PLC patients (Fig. 6a-c). 383 
 384 
Of particular interest was the substantial inhibition of tumouroid formation following 385 
inhibition of ERK1/2 by SCH772984 in HCC1-3, CC-1 and CHC-1 cells (Fig. 6a-d and 386 
Supplementary Fig. 8a). SCH772984, which selectively inhibited ERK-phosphorylation in 387 
HCC-1 and CC-1 tumouroids (Supplementary Fig. 8b), was effective in lines that were 388 
insensitive to the BRAF and/or MEK inhibitors in our screen (Dabrafenib and Trametinib) 389 
(Fig. 6c). The reason for this difference is unclear, although ERK inhibitors have 390 
demonstrated activity in cells with acquired BRAF and MEK inhibitor-resistance51.  391 
We note that clinical trials exploring the effect of specific ERK inhibitors for PLC have not 392 
been reported thus far. Hence, to further investigate the potential of ERK1/2 inhibition for 393 
PLC, we tested the efficacy of SCH772984 to inhibit tumour growth in vivo. For that, CC-1 394 
and HCC-1-derived tumouroids were transplanted subcutaneously into NSG mice and, when 395 
tumours reached ~100mm3, those were injected intra-tumourally with either SCH772984 or 396 
the vehicle. Remarkably, 2-7 days after the first injection we observed a significant reduction 397 
in tumour growth, which lasted for the remainder of the experiment (Fig. 6e and 398 
Supplementary Fig. 8c). Histological analysis revealed that the tumour mass was necrotic and 399 
that the majority of the cells were apoptotic (Fig. 6f-g and Supplementary Fig. 8d). Western 400 
blot analysis confirmed that SCH772984 also in vivo selectively inhibited ERK-401 
phosphorylation in CC-1 tumours (Supplementary Fig. 8e). Thus, in aggregate, our proof-of-402 
concept study demonstrates the application of PLC tumouroids for in vitro and in vivo drug 403 
testing, and provides initial evidence that ERK inhibition could have a beneficial therapeutic 404 
effect on a subset of HCC and CC patients.  405 
 406 
Overall, these results indicate that by faithfully retaining the histological, transcriptomic and 407 
genomic landscape of their parent tumour, tumouroid cultures facilitate the prediction of drug 408 
sensitivity/resistance in a patient-specific manner. Therefore, they provide an important new 409 
resource for liver cancer research, opening up new avenues for biomarker discovery and drug 410 
testing. 411 
  412 
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DISCUSSION 413 
 414 
The advent of 3D culture systems has made it possible to partially recapitulate the complexity 415 
and function of mammalian tissue in vitro, by forming structures that resemble an adult organ 416 
in culture and which have been termed “organoids”14. We recently have demonstrated that 417 
gastric, pancreatic and hepatic organoid cultures derived from adult tissues self-renew and 418 
differentiate in vitro, into the corresponding cell types of the tissue-of–origin14-15. 419 
 420 
Here, we demonstrate the proof-of-concept that primary liver cancer (PLC) tissue grown as 421 
organoid cultures (here termed tumouroid) faithfully models the genetic complexity of human 422 
PLC in vitro. We successfully established cultures from tumours derived from 8 PLC patients 423 
representing the three most common subtypes of PLC3: HCC, CC and CHC. In contrast to 424 
any liver cancer cell line grown in 2D, PLC-derived organoids recapitulate the histological 425 
architecture and expression profiles of the corresponding parent tumour, even after long-term 426 
expansion in the same culture conditions for all subtypes or upon transplantation into mice. 427 
Notably, they also retain the specific differences between patients as well as between tumour 428 
subtypes. We have exploited this aspect here to demonstrate the proof-of-concept that 429 
tumour-derived organoid cultures could represent a valuable resource for biomarker 430 
discovery, especially for prognostic markers, an application not previously reported for any 431 
organoid culture system. We report C19ORF48, UBE2S, DTYMK (for HCC) and C1QBP and 432 
STMN1 (for CC) as all novel genes associated to poor prognosis for primary liver cancer. 433 
Further studies, though, will be necessary to prove their utility as prognostic or their relevance 434 
as predictive biomarkers and/or their potential direct involvement in the progression of the 435 
disease. These results open up novel opportunities in using tumour-derived organoids for 436 
tumour marker discovery. 437 
 438 
A unique and important feature of the tumouroids is that they maintain the mutational 439 
landscape of the original patient’s tumour, even after long-term expansion in culture. This is 440 
vastly different to existing 2D cell lines, which albeit they cover the major driver mutations 441 
observed in many cancer sub-types52, no longer present the patient-specific signature and 442 
genetic landscape of the original tumours from whence they were derived, exemplified by the 443 
frequent acquisition of mutations in TP53 in such cell lines53. The reasons for these 444 
differences are unknown, but it is feasible to speculate that the cell-matrix interactions may 445 
play an important role. In fact, embedding primary tumoural epithelial cells within an 446 
extracellular matrix (ECM) enables the cells to interpret the environment and self-assemble 447 
into structures which acquire tissue patterning, as it occurs during development and 448 
organogenesis. Also, the cell-matrix interactions established in 3D could prevent anoikis-449 
apoptosis due to detachment from the matrix54- of those tumoural cells that have not acquired 450 
yet all the mutations to survive in a ECM-free milieu, thus facilitating the maintenance of 451 
heterogeneous, non-selected populations within the culture. In that line, our results indicate 452 
that if selection of specific tumoural cells exist in the cultures, this might have a minor effect 453 
at the population level, as we found that tumouroids harbour >92% of the SNVs present in the 454 
original tissue.  455 
 456 
The reproduction of parent tumour genetic aberrations in a culture setting makes tumouroid 457 
lines a potentially valuable resource in screening drug sensitivity/resistance, identifying novel 458 
players in primary liver cancer, or even novel therapeutics as part of a personalized medicine 459 
approach. Our results validate such an approach by (1) demonstrating a correlation between 460 
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some drug sensitivities and the mutational profile in the tumouroid lines and (2) the de novo 461 
identification of the ERK inhibitor SCH772984 as a potential novel therapeutic agent for 462 
PLC. Future studies aiming at validating the efficacy of ERK inhibition in a bigger collection 463 
of tumouroid lines will be required, though, to confirm its therapeutic value for liver cancer.  464 
The lack of immune system and stromal components, though, represents a limitation of the 465 
culture system, especially when aiming at studying tumour cell-stroma/immune interactions. 466 
In that regard, patient derived xenografts (PDXs) have proven useful models for human 467 
cancer, including liver cancer13,55, as they also retain tumour histopathology, including 468 
tumour-infiltrating lymphocytes and the stromal component, and global gene expression and 469 
methylation profiles of the patient’s malignant epithelial cells56. However, PDXs suffer from 470 
a low engraftment rate, especially CCs (5.8% engraftment efficiency as reported by Cavalloni 471 
et al.,13), have a long engraftment period (often several months), are expensive and time-472 
consuming, and are not tractable for large-scale drug sensitivity testing56. Therefore, we 473 
believe that the PLC-derived organoid cultures we present here are complementary and 474 
alternative models to liver cancer PDXs. Furthermore, they are suitable for large-scale drug 475 
testing, and in a timescale that makes it potentially compatible with personalized medicine 476 
approaches. 477 
 478 
In conclusion, the PLC-derived organoids that we present here fulfil all the criteria of a 479 
reliable in vitro cancer model, recapitulating all the features of three of the most common 480 
subtypes of liver tumours, from histological architecture to genetic and transcriptomic traits, 481 
and are amenable as a platform for drug screening. With a short timescale from establishment 482 
to drug testing, this novel in vitro primary liver cancer system thus makes hitherto 483 
inaccessible possibilities for predicting patient-specific drug responses and creating 484 
personalized/à la carte therapies into a reality. 485 
 486 
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FIGURE LEGENDS 677 
Figure 1: Patient-derived primary liver cancer organoid cultures expand long-term in 678 
vitro while preserving the histological architecture of the tumour subtype they derived 679 
from.  680 
(a) Experimental design. Healthy (donor-derived) liver tissues, moderate/well differentiated 681 
hepatocellular carcinoma (HCC), combined hepatocellular-cholangiocarcinoma (CHC) and 682 
cholangiocarcinoma samples (CC) were obtained from patients undergoing surgery (patient’s 683 
information detailed in Supplementary Table 1) and were processed as described in Methods 684 
and Supplementary Fig. 1. (b) Representative H&E staining of healthy liver tissue and 685 
primary tumours (top row), and corresponding brightfield microscopy images (middle row) 686 
and H&E histological analysis of the organoid lines derived from these (bottom row). Note 687 
that, while healthy liver-derived organoids (left) grew as single layered epithelium of ductal-688 
like cells surrounding a central lumen (*, duct; L, lumen), tumour-derived organoids 689 
(tumouroids; right) formed compacted structures that resembled the corresponding tumour-of-690 
origin. HCC-1 tumouroids, like their parental tissue, exhibit pseudoglandular rosettes 691 
(arrowheads), a hallmark of HCC. CC-1 tumouroids present a glandular lumen, similar to the 692 
patient’s tumour (top row). Scale bars, middle row 100µm; top and bottom rows, 50µm. 693 
Brightfield and H&E pictures from other lines are provided in Supplementary Fig. 2. (c) 694 
Organoid formation efficiency in classical human healthy liver isolation medium24-25 and 695 
tumouroid specific isolation medium (classical human healthy liver isolation medium without 696 
Rspo-1, Noggin and Wnt3a and 3nM Dexamethasone - see methods and Supplementary Fig. 697 
1 for details). Graph represents the mean±SD of the organoid formation efficiency in 698 
tumouroid IM relative to the one in classical IM. Individual data points are shown (circle). 699 
Significant differences between the classical and tumouroid IM groups were observed. **, p-700 
value<0.001 (t-test, two-tailed). (d) Expansion potential of tumouroid cultures established and 701 
their correlation to the expansion of healthy-tissue derived organoids. Arrow, continuous 702 
expansion. Dot, passage. 703 
 704 
Figure 2: Immunohistochemistry analyses reveal that the PLC tumouroids retain 705 
expression patterns of the distinct subtype of the original tissue they derived from, even 706 
after long-term expansion in culture.  707 
(a) Schematic representation of the multiple subtypes of primary liver cancers (PLC). (b) IHC 708 
assays on the PLC tissues including hepatocyte/HCC marker (HepPar1) and ductal/CC 709 
marker (EpCAM). Scale bar, 125 μm. Dashed red square indicates focal staining. (c) 710 
Immunofluorescent analysis for the HCC marker AFP (red) and the ductal/CC marker 711 
EpCAM (green), on tumouroids expanded in culture for at least 3 months. Nuclei were 712 
counterstained with Hoechst33342 (blue). Scale bar, 30µm. 713 
 714 
Figure 3: Tumouroids recapitulate the expression profiles of the specific tissue of origin. 715 
(a) Correlation heat map between PLC-tissue (_T) and paired PLC-derived organoid line (_O) 716 
expression profiles’ after at least >2 months expansion in culture. (b) Principal component 717 
analysis (PCA) showing samples plotted in 2 dimensions using their projections onto the first 718 
two principal components (PC1 and PC2). Each data point represents one sample (circle, 719 
tumouroid; triangle, tissue). PC1 is strongly correlated with the type of sample (tumouroids vs 720 
tissue) whereas PC2 defines the 3 different PLC subtypes (HCC, red; CHC, brown; and CC, 721 
green). Representative examples from the top-100 genes with highest loadings across PC2 are 722 
shown. (c) Heat map analysis of the log2 RPKM values (raw z-scored) of selected genes 723 
found highly expressed (red) in HCC and/or CHC and/or CC tumouroids. Top left column 724 
indicates whether the indicated genes are markers of HCC/Hepatocyte/Fetal liver/CC/Ductal 725 
or liver progenitor markers. (d) Heat-map indicating representative gene-sets significantly 726 
(False discovery rate (FDR)<25%) UPregulated (purple) and DOWNregulated (green) in the 727 
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tumouroid lines and paired tissues after performing gene set enrichment analysis (GSEA) 728 
comparing their gene signatures to 159 curated gene-sets associated with liver cancer and 729 
stem cell (representative plots are shown in Supplementary Fig. 5). Full list of gene-sets and 730 
significantly enriched gene-sets can be found in Supplementary Dataset 2 and 3. (e) 731 
Schematic of the tumouroid signature. Venn diagram overlapping the upregulated genes in 732 
each tumouroid line compared to healthy organoids. (f) Table summarizing the results of the 733 
gene expression (OE, overexpression) and outcome prediction (KM, Kaplan-Meier) analyses 734 
for the top 25-genes of the tumouroid signature using publically available TCGA cohorts. The 735 
table details the p-values obtained (OE, two-sided t-test ; KM, log-rank test). Statistical 736 
significance (p-value≤0.05) is denoted by yellow color. Values for the top 30-genes can be 737 
found in Supplementary Dataset 1. TCGA-HCC, 374 tumour/50 normal samples; TCGA-CC, 738 
31 tumour/8 normal samples. (g) Expression of STMN1, C1QBP and C19orf48 in tumour and 739 
normal tissues in the TCGA-HCC and/or CC cohorts. Center line, median; box plot, 740 
interquartile range (IQR); whiskers, range (minimum to maximum).  (h) Kaplan-Meier 741 
analyses of the TCGA-HCC and/or TCGA-CC cohorts based on the expression level of the 742 
indicated genes in the cohorts samples.  743 
 744 
Figure 4: Tumouroids preserve the genetic alterations from the original tumour  745 
(a) Ploidy analysis of tumouroid cultures expanded for at least 2 months in culture. Results 746 
are expressed as % of ploidy per number of metaphases counted (at least 21 total). Healthy-747 
derived organoids were used as control. A minimum of two independent experiments were 748 
performed. (b) Representative images of organoid metaphases used for the ploidy analysis. 749 
Scale bar, 10µm. (c-e) Whole exome sequencing analysis of patient's tumour tissues and 750 
corresponding tumouroid cultures expanded for < 2 months (early passage) or >4 months (late 751 
passage) in culture. All variants identified in all samples (21 total; 7 patients with 3 samples 752 
each (Tissue/early organoid/late organoid) were used for the global analyses after filtering for 753 
quality control as detailed in methods). (c) Correlation heat-map between the variants 754 
identified in PLC-tissues (_T) and PLC-tumouroids (_O). (d) Proportions of exonic variants 755 
across the samples, the 6 types of SNVs and the Indels are represented. (e) Percentage of the 756 
6 types of SNVs averaged across all samples. Graph represents mean±SD. (f-g) A cancer-757 
related set of variants (f) and variants predicted to impair protein function (SIFT score <0.05 758 
filter) (g) were identified as described in methods. (f) Bar plots indicate the concordance (%) 759 
between the cancer-related variants identified in the tumour-of-origin and the corresponding 760 
tumouroids expanded for short term in culture. (g) Damaging coding mutations found in 761 
genes already described mutated in liver cancer (Full list is found in Supplementary Dataset 762 
4, spread sheet 15 details the references). The type of mutation is indicated in the legend. _T, 763 
tissue; _O, organoid. 764 
 765 
Figure 5: In vivo growth and metastatic potential of PLC tumouroids  766 
(a) Experimental design. PLC tumouroids or Healthy liver-derived organoids expanded for >3 767 
months in culture were transplanted subcutaneously (SC) or under the kidney capsule 768 
(Kid.Cap.) of immunocompromised NSG mice and analysed for the presence of tumour 769 
growth and metastasis following grafting. (b) Tables summarizing the number of cells, site of 770 
engraftment and analysis of tumour and lung metastasis. No tumour lesions were found in any 771 
of the mice injected with Healthy-1 organoids. (c-d) Representative H&E staining of CC-1 (c) 772 
and HCC-1 (d) tumouroids transplanted subcutaneously (top) into NSG mice and 773 
corresponding patient’s tumour sample (bottom). (c) Note that the grafted CC-1 tumouroid 774 
tissue (top) recapitulates the histo-architecture of the patient’s original tumour (bottom) 775 
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including the extensive desmoplastic reaction (arrowheads). Scale bars, left 125µm, right 776 
62.5µm. (d) Note that the grafted HCC-1 tumouroid tissue recapitulates the histo-architecture 777 
of the patient’s original tumour (bottom) including the pseudoglandullar rosettes, hallmark of 778 
HCC-1 original sample (dashed circle). Scale bars, left 125µm, right 62.5µm. (e) 779 
Representative H&E (left) and KRT19 (right) immunohistochemistry analyses of CC-1 780 
tumouroids transplanted under the kidney capsule of NSG mice. Scale bar, 125µm. (f) Lung 781 
metastases derived from CC-1 tumouroids transplanted under the kidney capsule (right 782 
panels) were identified using a human specific KRT19 antibody. No metastases were found in 783 
the lungs of mice injected with Healthy-1 organoids (left panels). Scale bars, 500µm, 784 
magnifications 125µm. 785 
 786 
Figure 6. PLC tumouroid lines as a platform for drug screening and validation of 787 
actionable therapeutic targets.  788 
(a) Scatterplot of 1-AUC (Area Under the Curve) values from two biological replicates 789 
(different passages) of the drug screening data, highlighting drugs (red) having a potential 790 
effect on viability (AUC >0.15 for at least 1 of the two replicates) in the indicated tumouroid 791 
lines. Each data point is the 1-AUC value for a given drug in a particular tumouroid line. (b) 792 
Dose-response curves after 6 days treatment with Gemcitabine, Nutlin-3a, LGK974 and 793 
SCH772984 generated from the luminescent signal intensities. Data displayed are average of 794 
the technical and biological replicates. (c) Summary of the different compounds used in the 795 
drug screening, the associated pathway and nominal targets and the screen results represented 796 
as a summary of the 1-AUC and IC50 data generated for the different tumouroid lines. Red, 797 
IC50 within the screen concentration range (detailed in methods); Dense dotted pattern, 1-798 
AUC>0.15 and dose response; scattered dotted pattern, 1-AUC>0.15 and sensitivity at 799 
highest concentration only (Supplementary Dataset 5). Compounds highlighted in yellow 800 
were selected for further validation. (d) Effects on viability of indicated compounds using an 801 
organoid formation assay (detailed in methods). Red square, no viable cells; orange square, 802 
intermediate sensitivity; no square, resistant. Scale bar, 500μm. (e) In vivo activity of the 803 
ERKi (SCH772984) in CC-1_O tumouroids grafted subcutaneously in NSG mice. Mice were 804 
treated with drug/vehicle twice daily for 20 days (n=5 in 2mg/kg of SCH772984 group, n=8 805 
in vehicle group). *, p-value<0.01; **, p-value<0.002 (Mann Whitney test, two-tailed). 806 
Results are shown as percentage of the tumour volume relative to day 0 (mean ±SD). (f-g) 807 
Histological analysis of the antitumor efficacy of SCH772984 on CC-1_O tumours was 808 
assessed 24 days after starting the treatment. Representative (f) H&E and (g) TUNEL staining 809 
performed on tissue sections from CC-1_O tumours treated with either vehicle (left) or 810 
SCH772984 (right). Representative images from 2 independent experiments are shown. Scale 811 
bar, 125μm (H&E) and 25μm (TUNEL). 812 
 813 
Supplementary Figure 1: Isolation and culture of primary liver cancer-derived 814 
organoids. 815 
We successfully established and expanded human PLC-derived organoids from 7 different 816 
PLC patients, including poorly differentiated and moderate/well differentiated HCC (n=2), 817 
CC (n=3), and combined HCC/CC (CHC; n=2) by adapting the protocol to isolate and expand 818 
liver stem/progenitor cells24 for: (i) the timing of tissue digestion (2-5 hours to overnight 819 
(O/N) according to the degree of liver fibrosis in tumour specimen), (ii) the starting culture 820 
conditions (tumouroid specific isolation medium (IM)) and/or (iii) closely monitoring the 821 
developing organoid structures (in classical IM, healthy organoids might arise, depending on 822 
the type of tumour specimen. In those cases, these are hand-picked upon visual inspection). 823 
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After the first passage all tumouroid lines were maintained in the same culture conditions, our 824 
previously described “human healthy liver-derived organoid expansion medium”24-25. MWP, 825 
multi well plate; ROCKi, Rho kinase inhibitor (Y-27632).  826 
 827 
Supplementary Figure 2: Patient-derived PLC organoid cultures expand long term in 828 
vitro. 829 
(a) Tissues (top row) and tumouroids (middle and bottom rows) obtained from HCC-2, HCC-830 
3, CHC-2, CC-2 and CC-3 patients. H&E staining of the tumoural tissues (top), brightfield 831 
(middle) and H&E staining (bottom) pictures of tumouroids originated from the 832 
corresponding tissues. Scale bars, 125µm (top), 200µm (middle) and bottom 40µm, 125µm, 833 
125µm, 125µm and 70µm (left to right, respectively). (b-f) Representative Ki67 nuclear 834 
staining performed on patient’s tissues included in the study: (b) moderately differentiated 835 
HCC (HCC-1,-2), poorly differentiated HCC (HCC-3), (c) CHC (CHC-1 and CHC-2), (d) 836 
moderately/well differentiated CC (CC-1,-2) and poorly differentiated CC (CC-3), (e) well 837 
differentiated HCC (wHCC-8) and (f) well differentiated CC (wCC-1). Scale bars, 125µm. 838 
(g) Ki67-labelling index in PLC tissue samples. The percentage of tumour cells that are 839 
positive for nuclear Ki67 labelling was determined by counting a minimum of 1000 cells per 840 
patient in at least 2 independent slides. Graph represents mean±SD. Circle, individual data 841 
points. (h) Brightfield pictures of long-term expanded tumouroid cultures. Scale bar, 200µm. 842 
P, passage. 843 
 844 
Supplementary Figure 3: Immunohistochemistry and gene expression analyses reveal 845 
that PLC tumouroids retain expression patterns of the distinct subtype of the original 846 
tumour they derived from.  847 
(a) IHC analysis HepPar1 (hepatocyte/HCC marker) and EpCAM (ductal/CC marker) on CC-848 
3 tissue (_T). Scale bar, 125 μm. (b) EPCAM expression analysis (q-RT-PCR) in tumour 849 
tissues and respective tumouroid lines. Data are normalized to the expression of the 850 
housekeeping gene HPRT. Graph represents mean±SD of 2 independent experiments. Circle, 851 
individual data point. (c) PAS-diastase staining on tumoural tissues. Arrowheads mark 852 
positive PAS-diastase staining in CHC-1, CC-1 and CC-3 tissues (_T). Scale bar, 62.5 μm. 853 
(d) SALL4 expression analysis (q-RT-PCR) in tumour tissues and respective tumouroid lines. 854 
Data are normalized to the expression of the housekeeping gene HPRT. Graph represents 855 
mean±SD of at least 2 independent experiments. Circle, individual data point. 856 
 857 
Supplementary Figure 4: Transcriptomic analysis of tumouroids and matching tissues. 858 
(a) PCA analysis of the technical (same sample re-run) (a) and biological (same line different 859 
passage) (b) replicates. Each data point represents one sample. Dot, tumouroid line; triangle, 860 
PLC tissues. Of note, since the PCA analysis confirmed that technical and biological 861 
replicates are very close we averaged them for each patient line and in the manuscript we 862 
show the analysis per averaged patient sample. (c) Hierarchical clustering analysis of human 863 
primary liver cancer tissue samples based on gene expression (FPKM). Samples analyzed 864 
include human primary liver cancer specimens from publically available TCGA cohorts 865 
(TCGA-HCC, 344; TCGA-CC, 31) and the tumour specimens included in this study (HCC-1, 866 
-3 and CHC-1, -2 and CC-1, -2, -3 tissues). (d) Heatmap analysis of the log2 RPKM values 867 
(raw z-scored) of selected genes found highly expressed (red) in HCC and/or CHC and/or CC 868 
tumour specimen and corresponding tumouroids. 869 
 870 
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Supplementary Figure 5: Gene expression, immunohistochemistry and functional 871 
analyses reveal that the tumouroids retain the differentiation state of their original 872 
tissue, even after long-term expansion in culture. 873 
 (a) KRT19 IHC in the tissues used in this study. Scale bar, 125 μm. (b) IF analysis for the 874 
hepatocyte markers ALB and HFN4A (red) and ductal/CC marker KRT19 (green) on 875 
tumouroids expanded in culture for at least 3 months. Nuclei were counterstained with 876 
Hoechst33342 (blue). Scale bar, 30µm. (c) Representative GSEA plots for 2 gene-sets 877 
associated with PLC differentiation [HCC with hepatocyte differentiation features (Hoshida et 878 
al., 2009) and cholangiocarcinoma39] enriched in the tumouroid lines (_O). (d) Representative 879 
GSEA plots for 1 gene-set describing genes positively correlated with KRT19 expression 880 
(Govaere et al., 2013) in the tumoural tissues (_T). +, significantly upregulated; -, 881 
significantly downregulated; ns, non significant (FDR>25%). (e) Albumin secretion assessed 882 
by ELISA in the supernatant from HCC and CHC tumouroids. (f) Total bile acid production 883 
in HCC tumouroids. (g) KRT7 expression analysis (q-RT-PCR) in tumour tissues and 884 
tumouroid lines. Data is normalized to the expression of the housekeeping gene HPRT. All 885 
graphs (e-g) represent mean±SD of 2 independent experiments. Circle, individual data point. 886 
 887 
Supplementary Figure 6: Tumouroids recapitulate the genetic alterations present in the 888 
original tumour.  889 
(a-b) Whole exome sequencing analysis of patient’s tumour tissues and corresponding 890 
tumouroid cultures expanded for < 2 months (early passage) or >4 months (late passage) in 891 
culture. All variants identified in all samples (21 total; 7 patients with 3 samples (Tissue/early 892 
organoid/late organoid)) were used for the global analyses (a) after filtering for quality control 893 
as detailed in methods. For (b) a cancer-related set of variants was defined as detailed in 894 
methods. (a) Percentage of the 6 types of SNVs on transcribed and non-transcribed strand 895 
averaged across all samples. Graph represents mean±SD. (b) Summary table describing the 896 
coding concordant somatic acquired alterations present in all 3 samples per patient (tissue, 897 
tumouroids early and late passage). Red, deleterious variants among missense and structural 898 
variants (SIFT score <0.05 or N/A). (c) Representative GSEA plots for 1 gene-set describing 899 
genes up-regulated in tumours developed by transgenic mice overexpressing an EGF secreted 900 
form in liver46 significantly positively enriched in some of the tumouroid lines ( _O). +, 901 
significantly positively enriched (FDR<25%, p-value<0.05); ns, non-significant (FDR>25%).  902 
 903 
Supplementary Figure 7: Transplantation of PLC tumouroids in immunodeficient mice.  904 
(a) CC-2 and CC-3 tumouroids expanded for at least >3 months in culture were transplanted 905 
subcutaneously (posterior flanks) on immunocompromised NSG mice and analysed for the 906 
presence of tumour growth. Table summarizing the number of cells, site of engraftment and 907 
analysis of tumour in the different mice. (b) Representative images of the tumour growth after 908 
transplantation of tumouroids under the skin (SC) of immunodeficient mice. (c) Ki67 staining 909 
on xenografts developed under skin (SC) revealed that the tumours were highly proliferative. 910 
Scale bar, 125µm (top), 62.5µm (magnification). Similar data was obtained on xenografts 911 
developed under kidney capsule (data not shown). (d) Representative H&E staining of CC-2 912 
tumouroids transplanted subcutaneously (SC) into NSG mice and corresponding CC-2 913 
patient’s tumour tissue (bottom). Scale bars, 125µm (black), 62.5µm (inset). (e-f) Tumouroids 914 
were re-derived and expanded from xenografts derived from CC-1 tumouroids transplanted 915 
into the kidney capsule (Kid.Cap.) or HCC-1 tumouroids transplanted subcutaneously (SC) 916 
into immunocompromised NSG mice. (e) Representative brightfield and H&E staining 917 
images obtained after 5 passages in culture. Scale bar, 500µm (brightfield, top left), 200µm 918 
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(brightfield, top right) and 125µm (H&E staining). (f) Ploidy analysis of CC-1 and HCC-1 919 
tumouroids rederived from xenografted tumours. Number of metaphases counted, CC-920 
1_O_Kid.Cap.#1, n=15; CC-1_O_Kid.Cap.#2, n=16, HCC-1_O_SC#1, n= 12. Experiment 921 
was performed at least in duplicate. Note that morphology, histology and chromosome counts 922 
are maintained when comparing the parental tumouroids (derived directly from patient’s 923 
tumour) and the tumouroids rederived after xenografting. (g) Representative brightfield 924 
images of tumouroids transplanted under the kidney capsule (Kid.Cap.) of immunodeficient 925 
mice. Scale bar, 2 mm. (h) Representative brightfield images of lung metastasis found on 926 
mice grafted with CC-1 tumouroids under the kidney capsule. Scale bar, 2mm. Magnification 927 
2x.  928 
 929 
Supplemental Figure 8: PLC tumouroid lines can be used to identify gene-drug 930 
associations that may facilitate personalized therapy. 931 
(a) Scatterplot of area under the dose-response curve (AUC) values obtained for the drugs 932 
that were used to validate the drug screening using the tumouroid formation assay presented 933 
in Fig. 6d (Gemcitabine, Taselisib, Dasatinib, AZD8931 and SCH772984). Plots show the 934 
correlation between the two biological replicates for each tumouroid line. Each data point 935 
represents the area under the dose-response curve (1-AUC) value. Red, sensitive. Triangle, 936 
result further validated in the tumouroid formation assay. (b) Western blot analysis for 937 
phosphorylated ERK1/2 (P-ERK) and total ERK (ERK) in HCC1 and CC-1 tumouroid lines 938 
treated for 24 hours with either the pan-ERBB inhibitor AZD8931, the ERK inhibitor 939 
SCH772984 or with the vehicle. AZD8931 reduced ERK phosphorylation in HCC-1_O line 940 
only, whereas SCH772984 potently inhibited ERK phosphorylation in both HCC-1_O and 941 
CC-1_O lines, as expected according to their mutational profile (HCC-1_O, KRAS WT and 942 
CC-1_O, KRASG12D; see Fig. 4). Total ERK was used as loading control. Representative 943 
blots of 2 independent experiments are shown. (c) In vivo activity of SCH772984 in HCC-944 
1_O tumouroids grafted under the skin of NSG mice. Mice were treated with drug/vehicle 945 
twice daily for 15 days (n=3 in 2mg/kg of SCH772984 group, n=2 in vehicle group). 946 
Significant differences between the SCH772984 and the vehicle treated groups were 947 
observed. *, p-value<0.01 and **, p-value<0.002 (t-test, two-tailed). Results are shown as 948 
percentage of the tumour volume relative to day 0 (mean ±SD). (d) Histological analysis of 949 
the antitumour efficacy of SCH772984 on HCC-1_O tumours. Representative H&E staining 950 
on tissue sections from HCC-1_O tumours treated with either vehicle (left) or SCH772984 951 
(right). Representative images of 2 independent experiments are shown. Scale bar, 125uM. (e) 952 
Western blot analysis for phosphorylated ERK1/2 (P-ERK) and total ERK (ERK) in CC-1 953 
xenografted tumours dissected 6 hours after injecting SCH772984 (2mg/kg) or vehicle 954 
intratumourally. Total ERK was used as loading control. Representative blots of 2 955 
independent experiments are shown.  956 
 957 
Supplementary Table 1: Patients’ information and organoid efficiency derivation and 958 
expansion. 959 
Table summarizing the patient’s and healthy donor information including gender, age, type of 960 
tissue, histological analysis, Ki67 index and serum AFP levels. Organoid growth and 961 
expansion are indicated when appropriate. Efficiency of derivation and efficiency of organoid 962 
expansion are calculated. Note that all healthy tissues derived from healthy donors 963 
undergoing liver transplantation. N/A, not applicable; N/T, not tested. 964 
*Organoids from HCC-NL1 patient (derived at Erasmus Rotterdam Centre) became infected 965 
after some weeks in culture, and therefore were excluded from the analysis. 966 
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 967 
Supplementary Dataset 1: RNAseq data analysis. 968 
Dataset including S1-S8 tables summarizing all the RNAseq data analyses except GSEA (see 969 
Supplementary Dataset 2 and 3) and the TCGA analyses (survival & clustering). Used for 970 
Fig. 3 and Supplementary Fig. 4. 971 
Supplementary Dataset 2: Tumouroids GSEA data. 972 
Dataset including S1-S15 tables summarizing the tumouroids GSEA data used for Fig. 3 and 973 
Supplementary Fig. 5, 6 and 8. 974 
Supplementary Dataset 3: Tissue GSEA data. 975 
Dataset including S1-S15 tables summarizing the tissues GSEA data used for Fig. 3 and 976 
Supplementary Fig. 5, 6 and 8. 977 
Supplementary Dataset 4: WES. 978 
Dataset including S1-S15 tables summarizing the coding cancer-related variants found in 979 
short (early) and long (late) term expanded cultures and corresponding tissues used for Fig. 980 
4g and Supplementary Fig. 6b. 981 
Supplementary Dataset 5: Drug screening.  982 
Dataset including S1-S2 tables summarizing the List of drugs screened, their concentration 983 
and the data used for Fig. 6 and Supplementary Fig. 8 984 
Supplementary Dataset 6: List of antibodies, kits, and primers used. 985 
  986 
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ONLINE METHODS  987 
General experimental approaches. 988 
No samples, mice or data points were excluded from the reported analyses. Detailed 989 
information on experimental design and reagents is available through the accompanying Life 990 
Sciences Reporting Summary and Supplementary Dataset 6. Raw data used to generate 991 
figures are provided in Datasets 1-6 and Source data files 1 and 2. 992 
Human specimens 993 
Liver tumour specimen (~1-4 cm3) were obtained from resection performed at Erasmus 994 
Medical Center Rotterdam (MEC-2013-143), Cambridge University Hospitals NHS Trust 995 
(REC: 15/LO/0753 - Approval by NRES Committee London – Westminster) and The Royal 996 
Infirmary Hospital Edinburgh (REC: 15/ES/0097) on patients who had no history of viral-997 
meditated hepatitis (excluded under Institutional safety guidelines). Handling and processing 998 
of samples was performed according to HTA guidelines. Healthy liver resections (~1cm3) 999 
were obtained during liver transplantation performed at the Erasmus Medical Center, 1000 
Rotterdam MEC-2014-060 and at the Cambridge University Hospitals NHS Trust REC: 1001 
15/EE/0152. The Cambridge samples were provided by the Cambridge Biorepository for 1002 
Translational Medicine (CBTM). All patients provided informed consent. Samples were 1003 
procured and the study was conducted under Institutional Review Board approval prior to 1004 
tissue acquisition. Samples were confirmed to be tumour or normal based on 1005 
histopathological assessment. The diagnosis of each case was confirmed on routine 1006 
hematoxylin and eosin-stained slides by an independent histopathologist. For each tumour 1007 
specimen, samples were split into 4 parts and processed for histology, RNA and DNA 1008 
isolation, or dissociated and processed for organoid culture. 1009 
Isolation and Culture of human liver healthy and tumoural organoids 1010 
Healthy liver-derived organoids were isolated and cultured using our previously described 1011 
method24,25 while tumour-derived organoids (tumouroids) were isolated by adapting this 1012 
method as follows. Briefly, ¼ of the patient-derived or healthy donor specimen (~0.25 to 1013 
1cm3) was minced and incubated at 37°C with the digestion solution. Incubation was 1014 
performed for 30min-1h for healthy donor tissue (as described in ref 24) while for patient-1015 
derived tissue digestion was left for 2-5 hours to overnight (O/N) according to the degree of 1016 
liver fibrosis, which was evaluated in a patient-specific basis by visual inspection under a 1017 
stereomicroscope as well as according to the resistance of the tissue to be minced. For patient-1018 
derived tissue, after 2-5h digestion, the digestion preparation was visually inspected and 1019 
either digestion was stopped or, if a significant part of the original tissue was still under-1020 
digested (>50% of starting material, depending on the fibrotic status of the tissue), the 1021 
preparation was left o/n at 37°C in the digestion solution, in order to get a good yield of 1022 
tumoural cells. This increase in the digestion times compared to healthy tissue (>2h-o/n) 1023 
facilitated reducing the number of viable healthy contaminating duct cells. In all cases, the 1024 
digestion was stopped once no pieces of tissue were left, and the suspension was then filtered 1025 
through a 100µm nylon cell strainer and spun 5 min at 300-400G. The pellet was washed in 1026 
cold Advanced DMEM/F12 (GIBCO) then mixed with BME (Basement Membrane Extract, 1027 
Type 2, Pathclear). 2.000-5.000 cells were seeded per well in a 24-multi-well plate. After 1028 
BME had solidified, half of the wells obtained for each sample were cultured in the classical 1029 
human liver organoid isolation medium (Advanced DMEM/F12 supplemented with 1% 1030 
Penicillin/Streptomycin, 1% Glutamax, 10 mM HEPES, 1:50 B27 supplement (without 1031 
Vitamin A), 1:100 N2 supplement, 1.25mM n-Acetyl-L-cysteine, 10% (vol/vol) Rspo-1 1032 
conditioned medium, 30% (vol/vol) Wnt3a conditioned medium, 10mM nicotinamide, 10nM 1033 
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recombinant human [Leu15]-Gastrin I, 50ng/ml recombinant human EGF, 100ng/ml 1034 
recombinant human FGF10, 25ng/ml recombinant human HGF, 10μM Forskolin, 5μM 1035 
A8301, 25ng/ml Noggin and 10μM Y27632 as described in ref 24). The other half were 1036 
cultured in a tumouroid specific isolation medium (classical human liver organoid isolation 1037 
medium without Noggin, Rspo-1 and Wnt3a conditioned media but supplemented with 3nM 1038 
Dexamethasone (Sigma Aldrich). Thus, the tumoroid isolation medium contained: Advanced 1039 
DMEM/F12 supplemented with 1% Penicillin/Streptomycin, 1% Glutamax, 10 mM HEPES, 1040 
1:50 B27 supplement (without Vitamin A), 1:100 N2 supplement, 1.25mM n-Acetyl-L-1041 
cysteine, 10mM nicotinamide, 10nM recombinant human [Leu15]-Gastrin I, 50ng/ml 1042 
recombinant human EGF, 100ng/ml recombinant human FGF10, 25ng/ml recombinant 1043 
human HGF, 10μM Forskolin, 5μM A8301, 10μM Y27632 and 3nM Dexamethasone). It is 1044 
important to always culture half of the sample in classical isolation medium and half in our 1045 
tumouroid specific isolation medium, to ensure growth of the cultures. For instance, CC-1 1046 
patient material only grew in classical isolation medium because it requires Rspo-1 to grow. 1047 
For this line, though, we enriched for the tumouroids by hand-picking out contaminating 1048 
healthy organoids (as described in Supplementary Fig. 1). 1049 
After isolation medium was changed twice a week. For healthy-donor derived organoids, 1050 
isolation medium was changed to “human healthy liver-derived organoids expansion 1051 
medium” after 1-week in culture (see composition below). For tumouroids, isolation medium 1052 
(classical or tumouroid specific) was maintained until the first split. For tumouroid culture 1053 
establishment, after 2-3 weeks in culture (depending on the sample) the growing structures 1054 
were visually inspected and, if required, contaminating healthy organoids were hand-picked 1055 
to prevent these from outgrowing the tumouroid structures. Upon attainment of dense culture 1056 
(healthy liver-derived organoids (1-2 weeks after isolation) and tumour-derived organoids (2-1057 
3 weeks after isolation) were passaged by mechanical dissociation into small fragments via 1058 
trituration with a glass Pasteur pipet, and transferred to fresh matrix in the previously defined 1059 
“human healthy liver-derived organoids expansion medium”24,25 : Advanced DMEM/F12 1060 
supplemented with 1% Penicillin/Streptomycin, 1% Glutamax, 10 mM HEPES, 1:50 B27 1061 
supplement (without Vitamin A), 1:100 N2 supplement, 1.25mM n-Acetyl-L-cysteine, 10% 1062 
(vol/vol) Rspo-1 conditioned medium, 10mM nicotinamide, 10nM recombinant human 1063 
[Leu15]-Gastrin I, 50ng/ml recombinant human EGF, 100ng/ml recombinant human FGF10, 1064 
25ng/ml recombinant human HGF, 10μM Forskolin and 5μM A83-01)24. Expansion medium 1065 
was changed twice a week and cultures were split upon attainment of dense culture. 1066 
All cultures were tested every month for mycoplasma using the ‘PCR Mycoplasma Test kit 1067 
I/C’ kit from Promega in accordance with the manufacturer’s instructions. 1068 
To prepare frozen stocks, organoid cultures were dissociated and mixed with recovery cell 1069 
culture freezing medium (GIBCO) and frozen following standard procedures. When required, 1070 
the cultures were thawed using standard thawing procedures and cultured as described above. 1071 
For the 3-4 days (organoids) or first 2 weeks (tumouroids) after thawing, the culture medium 1072 
was supplemented with Y-27632 (10μM). Organoid pictures were taken with either a Leica 1073 
M80 stereoscope and Leica MC170 HD camera or with an inverted microscope Leica DMIL 1074 
and Leica DFC 450C camera. 1075 
Histology and staining 1076 
Tissues and organoids were fixed for 24 or 0.5 hours respectively, in 10% neutral buffered 1077 
formalin (Sigma), at room temperature, and then embedded in paraffin as follows: briefly, 1078 
tissues were processed through a graded ethanol series followed by xylene, and then 1079 
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embedded in paraffin, cut at 5μm and stained (H&E and immunohistological staining). For 1080 
immunofluorescence experiments fixed organoids were rehydrated with PBS following 1081 
formalin fixation. For immunohistological staining, paraffin slides were deparaffinised and 1082 
subjected to antigen retrieval using citrate sodium solution pH=6. To reduce background 1083 
nonspecific staining, and permeabilise the sample, slides were incubated with a 3% BSA, 1084 
0.5% Triton in TBS solution for 1 hour. Primary antibodies (listed in the Supplementary 1085 
Dataset 6) were then applied at appropriate dilutions for overnight at 4°C (see Supplementary 1086 
Dataset 6 for details). Endogenous peroxidase activity was blocked for 15 min in a 3% 1087 
hydrogen peroxide/methanol buffer. Detection of bound antibody was accomplished with the 1088 
BrightVision Ultimate kit (Immunologic). Briefly, slides were washed in TBS and incubated 1089 
with a secondary antibody-HRP conjugate for 1 hour at room temperature and finally 1090 
developed with 3,3′-diaminobenzidine (DAB) for 5 min, counterstained with haematoxylin, 1091 
and mounted with DPX (Sigma). Slides were also stained in the absence of primary 1092 
antibodies to evaluate nonspecific secondary antibody reactions. For TUNEL assay, Click-iT 1093 
Plus TUNEL kit (Molecular Probes, Life technologies) was used in accordance with the 1094 
manufacturer’s instructions. Pictures were taken with a Leica microscope DM 4000 1095 
microscope and DFC 450 camera (Leica). For whole mount immunofluorescence staining, 1096 
organoids were processed as described in 23,24 25. Briefly, organoids were incubated over 2 to 1097 
3 nights at 4°C, washed in PBS, and revealed by incubation with a secondary antibody 1098 
conjugated to a fluorophore. Nuclei were stained with Hoechst33342 (Molecular Probes, Life 1099 
technologies). Confocal images were captured on a Leica SP5 inverted confocal microscope 1100 
(Leica).  1101 
Ki67 index 1102 
Each tumour slide stained for Ki67 was manually scanned with a microscope at ×10 1103 
objective, and the area of greatest Ki67 positivity (hot spot) was selected for photographing. 1104 
At least 1000 total tumoural cells were counted on a total of 2 independently stained slides 1105 
per patient. Pictures were taken with a Leica microscope DM 4000 microscope and DFC 450 1106 
camera (Leica) and Ki67-negative and -positive were then counted using ImageJ “cell 1107 
counter” plugin. Light brown or pale staining nuclei were ignored during counting. 1108 
Karyotyping 1109 
Karyotyping was performed as previously described 24. Briefly, cultures were incubated with 1110 
0.1ug/ml Karyomax Colcemid (Gibco). After 24 hours, organoids were harvested and 1111 
dissociated using TrypLE (Gibco). Cells were incubated with KCL 0.0075M hypotonic 1112 
solution for 10 min, fixed in methanol:acetic acid (3:1) and dropped on a microscope slide for 1113 
visualization. Nuclei were mounted and stained using Vectashield with DAPI (Vector Labs). 1114 
A minimum of 15 metaphases per sample were counted. 1115 
Sequencing and analysis  1116 
For both RNA-Sequencing (RNASeq) and Whole-Exome Sequencing (WES), low quality 1117 
reads were filtered (<Q20) followed by trimming of low quality bases from the ends of the 1118 
reads (<Q20). Adaptors were also removed using cutadapt. 1119 
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RNA-Sequencing. RNA was isolated from organoids using RNeasy mini kit (Qiagen) 1120 
following manufacturer's instructions. RNA libraries were prepared for sequencing using the 1121 
Smartseq2 method. RNA sequencing was performed using Illumina HiSeq sequencer (50bp 1122 
single-end reads and 10-20 million reads were generated for each sample). Reads were 1123 
aligned with Tophat (v2.1.0)57 to the GRCh38.82 genome, using the corresponding gtf file for 1124 
exon positions. Counts were generated using featureCounts (v1.5.0-p1)58. Only protein-1125 
coding genes, lincRNAs, processed transcripts and misc RNA were kept for further study. 1126 
Normalised counts were created using DESeq259 and RPKMs using edgeR's function 1127 
[edgeR]. The technical and biological replicates (different passages) were merged. Healthy 1128 
growing in expansion and differentiation medium and corresponding tissues were used as 1129 
additional controls.  1130 
To assess concordance of tissues with organoids genes were filtered and the Pearson’s 1131 
correlation coefficient was calculated pairwise between tissues and organoids. The correlation 1132 
matrix was then z-scored. The principal components for several subgroups of the samples 1133 
were calculated from the normalised DESeq counts, and the first two (PC1, PC2) were 1134 
plotted. We then analysed the top 100 genes with highest loadings across PC2, which 1135 
separated the samples by subtype. Functional analysis was split across the three subtypes, and 1136 
genes were excluded in each unless healthy or tumour samples had RPKM values greater than 1137 
1. To generate a statistic for tumoural tissue samples, the log2 fold change (FC) of each 1138 
tumoural tissue was divided by the mean of the healthy tissues. To generate a statistic for 1139 
HCC tumouroid samples, two log2 fold changes (FC) were calculated: the first was HCC 1140 
organoid divided by the mean of healthy liver-derived organoid and the second was HCC 1141 
tissue divided by the mean of the healthy tissues. Then the mean or minimum was then taken 1142 
of these two ratios, whichever had a lower absolute value. The same statistic was generated 1143 
for CHC and CC tumouroids using the mean healthy tissue instead of healthy liver-derived 1144 
organoid as a baseline for the first fold change. These statistics were then used for pre-ranked 1145 
gene set enrichment analysis using GSEA software (http://www.broadinstitute.org/gsea/)60. 1146 
159 gene sets were used for running the GSEA. These gene sets were obtained after curation 1147 
of the publically available C2 MSigDB collection for “LIV”, “HEPT” and “STEM” key 1148 
words and completed by available liver cancer gene set described in literature (see 1149 
Supplementary Dataset 2 and 3) in order to select a relevant list of gene sets associated with 1150 
liver cancer and stemness. 1,000 permutations were used to calculate p-value. A tumouroid 1151 
signature was identified by finding genes with the highest FC when dividing the minimum 1152 
expression value, in RPKMs, over all tumouroid samples by the mean of the expression of 1153 
healthy liver-derived organoids in differentiation medium. Several aspects of the genes 1154 
defining the tumouroids' signatures were annotated: the description of their corresponding 1155 
proteins was downloaded from Uniprot61, and their relevance to disease by retrieving the 1156 
Disease Ontology terms (using the R package dnet v1.0.1062).  1157 
WES. DNA from tumour tissue and matched tumouroid lines was extracted using DNeasy 1158 
Blood & Tissue Kit (Qiagen) according to manufacturers' protocol. Point mutations and short 1159 
indels were called in a procedure composed of several steps as follows: (i) Reads were 1160 
aligned to the UCSC hg38 genome using Bowtie2 (v2.2.6)63 and the output was preprocessed 1161 
for variant calling by marking duplicates with Picard (v1.113) 1162 
(http://broadinstitute.github.io/picard/) followed by Indel realignment with the GATK toolkit 1163 
(v3.7)64. SNPs and Indels were called with Varscan (v.2.3)65. (ii) We identified and selected 1164 
the variants with the following parameters: base quality ≥15 (Phred score), read depth ≥15 1165 
and annotated by SNPEff66 as not “intergenic”. (iii) We removed variants on alternate 1166 
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haplotypes. (iv) Analysis was then split between patients. For each, there were 3 samples, the 1167 
tissue and the corresponding tumouroids expanded for <2months (early) or >4months (late). 1168 
If a variant was called in the ‘early’ sample, a variant was added in the tissue if its pileup 1169 
showed evidence of the same variant at that position. Moreover if a variant was called in the 1170 
‘late’ sample, a variant was added in the tissue and early sample if their pileup both showed 1171 
evidence of the same variant at that position. Fig. 4c-e and Supplementary Fig. 5a are based 1172 
on this final list of variants. To assess concordance, overlaps of variants found in tissue and 1173 
early and late tumouroids were calculated within and between cancer types using GATK 1174 
(v3.7). The mutation spectrum was examined in each sample in both non-transcribed and 1175 
transcribed strands and then summarized by representing the average proportion across all 1176 
samples. A cancer-related set of variants was defined by adding the following filtering steps: 1177 
(v) To filter out polymorphisms and non-damaging variants we exclude variants which had 1178 
reads supporting variations ≥ 2 in our sequenced healthy samples (Healthy-1_Tissue and 1179 
_Organoid; Healthy-2_Organoid) and / or were included in dbSNP (common _ no _ known _ 1180 
medical _ impact _ 20170801.vcf )67 and / or with a frequency >0.01 in ExAC database68. To 1181 
select for cancer related variants we then (vi) filter for the variants present in COSMIC 1182 
(v76)69, and (vii) synonymous and intronic variants were filtered out. The variant positions 1183 
with their associated effects were annotated with SnpEff66. Resultant variants were used for 1184 
the Fig. 4f. (viii) Finally, we selected the mutations that were highly predicted to impair the 1185 
function of the corresponding encoded proteins by filtering for coding mutations and using 1186 
SIFT70) to predict the deleterious (SIFT score <0.05) impact of missense and structural 1187 
variants. A summary of the concordant (tissue/early/late) coding variants obtained per patient 1188 
is provided in Supplementary Dataset 4 and this final list of variants was used for 1189 
Supplementary Fig. 6b and Fig. 5g. 1190 
Accession Numbers 1191 
All RNA-seq and WES data are available at Gene Expression Omnibus (GEO) under 1192 
accession number GSE84073.  1193 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84073 1194 
The Cancer Genome Atlas (TCGA) analyses 1195 
We used public available data generated by the TCGA Research Network: 1196 
http://cancergenome.nih.gov/ to perform hierachical clustering and survival outcome 1197 
analyses. FPKMs were downloaded from the Genomic Data Commons Data Portal (GDC), 1198 
using GDC’s API, for the projects TCGA-LIHC (374 tumoral samples (ICD-O-3 1199 
number=C22.0) and 50 normal control samples) and TCGA-CHOL (31 tumoral samples 1200 
(ICD-O-3 number=C22.1) and 8 normal control samples). 1201 
For the hierarchical clustering our sequencing data was processed according to the GDC 1202 
mRNA quantification analysis pipeline to obtain FPKM values comparable with the ones 1203 
from the TCGA-cohorts. The hierarchical clustering used the Euclidean distances between 1204 
samples based on the top 500 expressed genes and was performed using hclust in R and 1205 
plotted using the dendextend R package71. Healthy, not annotated for the stage of the disease 1206 
and recurrent disease samples were excluded from the analysis. 1207 
For the survival analysis we examined the expression of the top 30 genes of the tumouroid 1208 
signature, in both TCGA-LIHC and TCGA-CHOL cohorts. From the FPKM values of 1209 
tumoral and control samples we generated base R boxplots (R’s default boxplot code) and 1210 
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assess the significance between both group by unpaired two-tailed t-test. Survival plots were 1211 
created using the R package TCGAbiolinks (v2.2.10)72 and by splitting, per gene, the tumour 1212 
samples into high- and low-expression groups. The median of all samples was used as the 1213 
threshold and significance for differences between the two groups was assessed by log-rank 1214 
test. 1215 
Quantitative RT-PCR 1216 
Total RNA was extracted from organoid cultures or freshly isolated tissues using RNeasy 1217 
mini kit (Qiagen) in accordance with the manufacturer’s instructions. cDNA was synthesized 1218 
using 0.5μg of total RNA and a M-MLV Reverse Transcriptase kit (Promega). cDNA was 1219 
amplified with iTaq™ Universal SYBR Green Supermix (BioRad) and using gene-specific 1220 
primers described in Supplementary Dataset 6). All targets were amplified (40 cycles) on a 1221 
CFX96 Touch Real-Time PCR Detection System (Biorad). Data were analyzed using BioRad 1222 
CFX manager. Expression levels were normalized to the expression of the housekeeping gene 1223 
HPRT. 1224 
Functional in vitro studies 1225 
Functional studies were performed in collected supernatant or in whole organoids. To assess 1226 
albumin production, culture medium was collected 1 week after the last medium change and 1227 
albumin levels were assessed using an Albumin ELISA kit (Assay Pro) according to 1228 
manufacturer’s instructions. Values were corrected for time and cell number. Concentration 1229 
of total bile acid was established using a Total Bile Assay kit (Cell Biolabs, inc.) according to 1230 
manufacturer’s instructions on supernatant obtained after sonication of whole organoids in 1231 
PBS. 1232 
Organoid formation Assay 1233 
To assess the organoid formation efficiency in classical vs tumouroid isolation medium, 1234 
pictures of all full drops of BME obtained per patient were photographed using a Leica M80 1235 
stereoscope 2-3 weeks after isolation (depending on the sample) and all viable tumouroid 1236 
structures were counted. 1237 
For the drug sensitivity assays, organoids were dissociated into 2-5 cell clumps by enzymatic 1238 
dissociation with TrypLE (Life Technologies). Then, cell viability assays were conducted by 1239 
plating 500 clumps per well of a 48-well cell culture plate in 250μl of expansion medium 1240 
supplemented with 0.5 μM Gemcitabine (Actavis), or 5 μM of AZD8931 (Selleckchem), or 1241 
10μM of SCH772984 (Selleckchem) or 2μM Dasatinib (Selleckchem) or 10μM of Taselisib 1242 
(Selleckchem) or 3μM of IWP2 (Sigma Aldrich) or 1μM of Gefitinib (Selleckchem) or 1243 
vehicle (DMSO) control. All conditions were supplemented with Rho kinase inhibitor Y-1244 
27632 (Sigma-Aldrich). The concentration selected for each compound was based on the cell 1245 
viability data from our laboratory, the results from the screening or the literature. Medium 1246 
was changed 3 times a week for 3 weeks. Viable cells were assessed by their ability to 1247 
generate organoid de novo. Representative pictures of the viability result were taken 2-3 1248 
weeks after starting the treatment. All cell viability experiments were conducted in triplicate 1249 
in at least two independent experiments (biological replicates = different passages). 1250 
Drug screening 1251 
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Organoid viability assays were conducted as previously described19,50. Briefly, 8µl of 1252 
~7mg/ml BME-2 was dispensed in to 384-well microplates and allowed to polymerize. 1253 
Organoids were mechanically dissociated by pipetting before being resuspended in 2% 1254 
matrigel/growth media (15.000-20.000 organoids/ml) and dispensed into 384-well plates. The 1255 
following day a concentration dilution series of each compound was dispensed using liquid 1256 
handling robotics and cell viability assayed using CellTiter-Glo® (Promega) following 6 days 1257 
of drug incubation. An experimental concentration range was calculated for each compound 1258 
using a 7-point half-log dilution series of the highest maximal concentration. The maximal 1259 
concentration of each compound can be found in Supplementary Dataset 5. Screens were 1260 
performed in technical (same screening run) and biological duplicates (different passage), and 1261 
all screening plates were subjected to stringent quality control measures and a Z-factor score 1262 
comparing negative and positive control wells was calculated. Dose–response curves were 1263 
fitted to the luminescent signal intensities utilizing a method previously described73. Variation 1264 
in replicates was greater than similar screens performed in colorectal tumouroids and was 1265 
likely due to the large size of HCC tumouroids leading to uneven distribution in screening 1266 
wells19,50. Compound and screening concentrations are provided in Supplementary Dataset 5. 1267 
The range of concentrations selected for each compound was based on in vitro data of 1268 
concentrations inhibiting relevant target activity and cell viability based on data from our 1269 
laboratory or literature. 1270 
Mouse xenograft studies 1271 
All mouse experiments have been regulated under the Animals (Scientific Procedures) Act 1272 
1986 Amendment Regulations 2012 following ethical review by the University of Cambridge 1273 
Animal Welfare and Ethical Review Body (AWERB) and have been performed in accordance 1274 
to the Home Office license awarded to M.H. For subcutaneous grafts, 1 million cells 1275 
suspensions were prepared in PBS-0.1%BSA (CC and healthy liver-derived organoid lines) or 1276 
in Advanced DMEM/F12 (GIBCO) 1% glycosil (ESI-BIO) further supplemented with 1277 
50 ng/ml each of HGF and VEGF (HCC and healthy liver-derived organoid lines) and were 1278 
injected into both flanks of male NSG-NOD scid gamma mice (Charles River). Visible 1279 
tumours developed in approximately 2–4 weeks (CC organoid lines) and 4-6 months (HCC-1 1280 
organoid line). Mice were culled when the tumour reached limit end-point (size or 1281 
ulceration). For kidney capsule graft, cell line suspensions were prepared in Advanced 1282 
DMEM/F12 (GIBCO) with BME2 (7mg/ml) and 500.000 cells were implanted under the 1283 
renal capsule of NSG mice. These mice were then culled at different time point (0.5, 1, 2 and 1284 
3 month) and kidney and lung tissues were harvested to assess the growth and the metastatic 1285 
potential of the grafted cells.  1286 
To assess the efficiency of the ERK inhibitor SCH772984 in vivo mice with established 1287 
subcutaneous tumours were randomized to drug treatment by splitting size-matched tumours 1288 
in two groups (SCH772984/vehicle). Treatments (SCH772984 at 2 mg/kg, or an equal 1289 
volume of vehicle (25%DMSO-30%PEG300 in DD water) were administered by 1290 
intratumoural injection twice daily for 15 (CC-1 tumouroid line) or 20 (HCC-1 tumouroid 1291 
line) days. Tumour sizes were measured 3 times a week after the first week of treatment using 1292 
a caliper and volumes were calculated by applying the formula v = 0.5 × L × w × h, where v 1293 
is volume, L is length, w is width and h is height. Investigators performing tumour 1294 
measurements were blinded to treatment groups. Histological analyses of the tumours from 1295 
both CC-1 and HCC-1 lines were performed at 24 and 25 days after treatment initiation 1296 
respectively. 1297 
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Western blot assay 1298 
Cell lysate for Western blotting were prepared from (i) ice-cold PBS washed tumouroids (to 1299 
remove the basement matrix) grown for 24 hours in expansion medium supplemented with 1300 
10μM of SCH772984 (Selleckchem), or 5 μM of AZD8931 (Selleckchem) or equal volume 1301 
of vehicle (DMSO) and from (ii) CC-1 xenografted tumours, 6 hours after intratumoural 1302 
injection of 2mg/kg of SCH772984 (Selleckchem) or equal volume of vehicle. Lysates were 1303 
made in ice-cold buffer consisting of 50mM Tris-HCl (pH 7.4), 150mM NaCl, 2mM EDTA, 1304 
50mM NaF, 1% triton, 1% NP-40. 0.1% SDS, 0.5% Na-deoxycholate, supplemented with 1305 
1mM sodium orthovanadate and protease inhibitor cocktail (Roche) (15min on ice for the 1306 
cells and 30min on ice for the tissues). Protein lysates were cleared by microcentrifugation at 1307 
10.000 rpm for 10 min at 4°C and the supernatants aliquoted and stored at −20°C. Equivalent 1308 
amounts of protein from each sample were separated on 10% SDS-PAGE gels and then 1309 
transferred by electroblotting onto nitrocellulose membranes. Membranes were then blocked 1310 
in in PBS-0.1% Tween-5% BSA and immunoblotted with the following antibodies overnight 1311 
at 4°C: ERK (1/2000), P-ERK (1/3000) (Cell signalling). After washing 3 times in PBS-0.1% 1312 
Tween, the membranes were incubated for 1h at room temperature with anti-rabbit 1313 
horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10.000; abcam). Antibody-1314 
protein complexes were visualised using ECL Prime Western Blotting Detection Reagent (GE 1315 
Healthcare). 1316 
Statistical Analyses 1317 
All summary data are presented as mean ± SD or representative images of at least 2 1318 
independent experiments. All statistical analyses were performed in R and GraphPad Prism 1319 
software (GraphPad 7.0). Sample size (n) values used for statistical analyses are provided in 1320 
the relevant figures and supplementary figures. Individual data point are graphed or can be 1321 
found in Source data files. Tests for differences between two groups were performed using 1322 
Mann-Whitney’s two-tailed test, Student's two-tailed unpaired t-test or log-rank test as 1323 
specified in the figure legends. When using t-test we assumed normality and equal 1324 
distribution of variance between the different groups. No data points were excluded from the 1325 
statistical analyses. Significance was set at FDR ≤ 0.25 (for GSEA) and p-value ≤ 0.05 (for 1326 
all other experiments).  1327 
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Supplementary Table 1Sample Gender Age Localisation
Sample Gender Age Localisation Nodal Metastasis Histological grade Ki67 index AFP ( g/L )
Differentiation 
status
Organoid 
growth
Organoid 
expansion
Derivation 
rate          
(%)
Expansion 
rate          
(%)
CC-1 F 34 Perihilar Yes CC mod/well diff. 2
CC-2 M 68 Intrahepatic (segment 5-6) No CC mod/well diff. 3
CC-3 M 64 Intrahepatic  (segment 4-5-8) No CC poorly diff. N/T
CHC-1 F 56 Segment 5 No CHC - Classical 512
CHC-2 F 61 Segment 5-6 Yes CHC - SC 1718
HCC-1 M 69 Segment 8 No HCC mod/well diff. 53
HCC-2 M 52 Segment (2-4), and caudate lobe No HCC mod/well diff. 469 x
HCC-3 F 71 Segment 7 N/A HCC mod diff. 1700
HCC-NL1* F 37 Segment 6 No HCC mod diff. N/T 19742 N/A N/A N/A N/A N/A
wCC-1 F 54 Intrahepatic (4-5) No CC well diff. N/T x x
wHCC-1 M 78 Segment 6 No HCC well diff. <2 x x
wHCC-2 M 57 Segment 2-3 No HCC well diff. 6 x x
wHCC-3 M 77 Segment 2-3 No HCC well diff. 2 x x
wHCC-4 F 70 Segment 2-3 No HCC well diff. 2 x x
wHCC-5 M 76 Segment 6-7 No HCC well diff. N/T x x
wHCC-6 M 75 Segment 2-3-4 No HCC well diff. 8 x x
wHCC-7 M 72 Segment 3 No HCC well diff. N/T x x
wHCC-8 M 66 Segement 4B No HCC well diff. 7 x x
Healthy-1 M 23
Healthy-2 F 44
Healthy-3 M 50
Healthy liver; biopsy obtained from donor tissue used for transplantation 100% 100%
 >5%
<5%
poorly to 
moderate/well 
differentiated
100% 88%
well 
differentiated 0% 0%
